Donald A Mahler1, Jill A Ohar2, Chris N Barnes3, Edmund J Moran3, Srikanth Pendyala3, Glenn D Crater3. 1. Geisel School of Medicine at Dartmouth, Hanover, New Hampshire and Respiratory Services, Valley Regional Hospital, Claremont, New Hampshire. 2. Wake Forest University Medical Center, Winston-Salem, North Carolina. 3. Theravance Biopharma US, Inc., South San Francisco, California.
Abstract
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) because of inadequate inspiratory flow. Nebulized bronchodilators may provide a better alternative. We compared bronchodilation with the long-acting muscarinic antagonist (LAMA) revefenacin for nebulization versus the DPI LAMA tiotropium, in patients with COPD and sPIFR (< 60 L/min against the resistance of Diskus®). METHODS: This was a randomized, double-blind, double-dummy, 28-day Phase 3b study in patients with COPD enrolled based on sPIFR. The primary endpoint was trough forced expiratory volume in 1 second (FEV1) on Day 29 for revefenacin for nebulization versus tiotropium HandiHaler® DPI. RESULTS: We enrolled 206 patients with mean (standard deviation) age, 65 (8) years; percent predicted FEV1, 37 (16)%; PIFR, 45 (12) L/min. In the intent-to-treat (ITT) population, revefenacin improved trough FEV1 from baseline; however, the difference versus tiotropium was not significant (least squares [LS] mean difference [standard error], 17.0 [22.4] mL, P=0.4461). In a prespecified analysis of patients with FEV1 < 50% predicted, revefenacin produced an LS mean difference (95% confidence interval [CI]), 49.1 (6.3-91.9) mL in trough FEV1 and 103.5 (7.7-199.3) mL in forced vital capacity versus tiotropium. Revefenacin produced >100 mL increase in FEV1 in 41.6% versus 34.4% of patients with tiotropium in ITT and 41.4% versus 25.7% of patients in FEV1 < 50% predicted populations. CONCLUSIONS: Revefenacin did not produce significant improvements in FEV1 versus tiotropium in the ITT population, but increased trough FEV1 in patients with FEV1 < 50% predicted and sPIFR. Clinical Trial Registration (www.Clinicaltrials.gov): Study 0149 (NCT03095456). JCOPDF
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) and suboptimal peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) because of inadequate inspiratory flow. Nebulized bronchodilators may provide a better alternative. We compared bronchodilation with the long-acting muscarinic antagonist (LAMA) revefenacin for nebulization versus the DPI LAMA tiotropium, in patients with COPD and sPIFR (< 60 L/min against the resistance of Diskus®). METHODS: This was a randomized, double-blind, double-dummy, 28-day Phase 3b study in patients with COPD enrolled based on sPIFR. The primary endpoint was trough forced expiratory volume in 1 second (FEV1) on Day 29 for revefenacin for nebulization versus tiotropium HandiHaler® DPI. RESULTS: We enrolled 206 patients with mean (standard deviation) age, 65 (8) years; percent predicted FEV1, 37 (16)%; PIFR, 45 (12) L/min. In the intent-to-treat (ITT) population, revefenacin improved trough FEV1 from baseline; however, the difference versus tiotropium was not significant (least squares [LS] mean difference [standard error], 17.0 [22.4] mL, P=0.4461). In a prespecified analysis of patients with FEV1 < 50% predicted, revefenacin produced an LS mean difference (95% confidence interval [CI]), 49.1 (6.3-91.9) mL in trough FEV1 and 103.5 (7.7-199.3) mL in forced vital capacity versus tiotropium. Revefenacin produced >100 mL increase in FEV1 in 41.6% versus 34.4% of patients with tiotropium in ITT and 41.4% versus 25.7% of patients in FEV1 < 50% predicted populations. CONCLUSIONS: Revefenacin did not produce significant improvements in FEV1 versus tiotropium in the ITT population, but increased trough FEV1 in patients with FEV1 < 50% predicted and sPIFR. Clinical Trial Registration (www.Clinicaltrials.gov): Study 0149 (NCT03095456). JCOPDF
Authors: James F Donohue; Jan A van Noord; Eric D Bateman; Stephen J Langley; Angela Lee; Theodore J Witek; Steven Kesten; Lesley Towse Journal: Chest Date: 2002-07 Impact factor: 9.410
Authors: Brendan Clark; Brian J Wells; Amit K Saha; Jessica Franchino-Elder; Asif Shaikh; Bonnie M K Donato; Jill A Ohar Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-06-29
Authors: Martin Anderson; Kathryn Collison; M Bradley Drummond; Melanie Hamilton; Renu Jain; Neil Martin; Richard A Mularski; Mike Thomas; Chang-Qing Zhu; Gary T Ferguson Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-04-12
Authors: Jill A Ohar; Gary T Ferguson; Donald A Mahler; M Bradley Drummond; Rajiv Dhand; Roy A Pleasants; Antonio Anzueto; David M G Halpin; David B Price; Gail S Drescher; Haley M Hoy; John Haughney; Michael W Hess; Omar S Usmani Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-01-06
Authors: Donald A Mahler; Andrea Ludwig-Sengpiel; Gary T Ferguson; Alberto de la Hoz; John Ritz; Asif Shaikh; Henrik Watz Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-08-28